Fig. 2

The effect of BI-847325 on the cell cycle distribution, apoptosis, and proliferation in C643 and SW1736 ATC cell lines. A, B After 48 h of drug intervention, C643 and SW1736 cells were subjected to cell cycle analysis by PI flow cytometry. The percentage of cells in sub-G1, G0/G1, S, and G2/M phases are indicated for each cell line. The untreated cells were considered as control. C, D Representative histogram of cell cycle analysis based on flow cytometry in 48 h after BI-847325 treatment of C643 and SW1736 compared to untreated cells as control. E, F Apoptosis assessment using Annexin V/PI flow cytometry in BI-847325 treated cells in comparison with untreated cells as control. G, H Graphical representation of early apoptosis, late apoptosis, and necrosis based on flow cytometry in 48 h after BI-847325 treatment of C643 and SW1736 compared to untreated cells as control. Cellular proliferation of untreated and treated cells was measured using flow cytometry 48 h after treatment. I, J CFSE histograms for C643 and SW1736. Orange histograms show 18 h after labeling, which confirms labeled but non-proliferating cells. K The diagram shows significantly higher fluorescence intensity and consequently lower proliferation in treated ATC cell lines compared to untreated cells. Statistical significances are expressed as p < .05 (*); p < .01 (**); p < .001 (***); p < .0001 (****)